RVL Pharmaceuticals, Inc and its affiliates announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq , 0.1%.
Health Technology Insights: Cancer Check Labs Expands Multi-Cancer Early Detection Test to New York
RVL’s Board of Managers has appointed Lori Deo as Chief Executive Officer. Lori was Executive Chairwoman of the Board for RVL prior to this appointment (the Chairperson role will now be held by affiliates of RVL’s majority shareholder, Athyrium Capital Management, LP). Lori is a dynamic and experienced healthcare executive with general management experience at world class companies including Johnson & Johnson and Pfizer. She has a proven track record of building and scaling brands and businesses across the healthcare and beauty landscape. As CEO, Lori will lead RVL’s strategy to expand market penetration and drive revenue acceleration, working in close partnership with the healthcare professional community.
Health Technology Insights: MediKarma Appoints New Chief Clinical and Revenue Officers
The company has also appointed Amy Shah as Chief Growth Officer. Amy is a transformational leader with a distinguished record of architecting growth strategies and inspiring high-performing teams across the pharmaceutical, OTC, and beauty landscape. During her 20-year career at Johnson & Johnson, she led enterprise reinvention, from pioneering integrated consumer experience models to advancing technology-driven engagement strategies that reshaped trajectories for leading brands. In this expanded role, Amy will be responsible for an integrated commercial organization across sales, marketing, innovation, and pipeline development.
“RVL is entering a pivotal next phase of growth,” said Lori Deo, Chief Executive Officer. “These leadership appointments strengthen our ability to scale, deepen engagement with consumers and healthcare providers, and fully capitalize on the category-defining potential of Upneeq, with an estimated $2.5B Total Addressable Market (TAM). We are committed to investing with intention to unlock TAM, build and scale a new category, and accelerate brand and platform momentum.”
Strong Commercial Momentum
Upneeq, the first and only FDA-approved prescription eye drop for acquired ptosis (low-lying eyelids), continues to demonstrate accelerated growth driven by expanding adoption, channel diversification and patient satisfaction.
“Recent commercial investments have driven a clear inflection, with Upneeq Q3 2025 revenue up 22% versus Q3 2024, and further quarter-over-quarter acceleration expected in Q4 2025. These results underscore the strength of the Upneeq brand and the continued effectiveness of our commercial strategy,” said Katerina Gembarski, Chief Financial Officer.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 19 November 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
